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Abstract ER resident glycoproteins, including
ectopically expressed recombinant glycoproteins,
carry so-called high-mannose type N-glycans, which
can be at different stages of processing. The presence
of heterogeneous high-mannose type glycans on
ER-retained therapeutic proteins is undesirable for
specific therapeutic applications. Previously, we
described an Arabidopsis alg3-2 glycosylation mutant
in which aberrant Man5GlcNAc2 mannose type N-gly-
cans are transferred to proteins. Here we show that the
alg3-2 mutation reduces the N-glycan heterogeneity on
ER resident glycoproteins in seeds. We compared the
properties of a scFv-Fc, with a KDEL ER retention tag
(MBP10) that was expressed in seeds of wild type and
alg3-2 plants. N-glycans on these antibodies from
mutant seeds were predominantly of the intermediate
Man5GlcNAc2 compared to Man8GlcNAc2 and
Man7GlcNAc2 isoforms on MBP10 from wild-type
seeds. The presence of aberrant N-glycans on MBP10
did not seem to affect MBP10 dimerisation nor binding
of MBP10 to its antigen. In alg3-2 the fraction of
underglycosylated MBP10 protein forms was higher
than in wild type. Interestingly, the expression of
MBP10 resulted also in underglycosylation of other,
endogenous glycoproteins.
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Introduction
Plants have a great potential as an expression system
for therapeutic proteins: plant produced pharmaceu-
ticals are much less likely to harbor human patho-
gens, production costs are relatively low and the
production is easily scalable, while products can
efficiently be harvested and stored (Fischer and
Emans 2000; Fischer et al. 2000; Giddings 2001).
Harvesting of pharmaceuticals from plants may be
greatly facilitated by directing expression of thera-
peutic proteins to the specialized storage organs of
plants (Peeters et al. 2001; Staub et al. 2000; Stoger
et al. 2000; Van Droogenbroeck et al. 2007). Many of
the potential therapeutic proteins, including antibod-
ies, require specific post-translational modifications
for correct biological functioning.
Core N-glycan biosynthesis is similar in mammals
and plants, but mammals and plants make different
complex-type N-glycans. These differences between
mammalian and plant N-linked glycan biosynthesis
limit the application of therapeutic glycoproteins
produced by plants since the plant produced proteins
may not have the desired biological properties
(Rayon et al. 1998). For instance, the plant specific
xylose and fucose of plant complex glycan structures
may trigger an immunogenic response in mammals,
making these plant specific modifications potentially
immunogenic to mammals (Bencurova et al. 2004).
Several approaches are being pursued to optimize
glycosylation in plants for pharmaceutical protein
production. Plant N-glycans can be extended by
mammalian type sugars through the introduction of
mammalian glycosyltransferases. Via such plants,
antibodies with N-glycans extended with b1,4-gal-
actose and even sialic acid were produced (Misaki
et al. 2003; Fujiyama et al. 2001; Bakker et al. 2001;
Palacpac et al. 1999; Strasser et al. 2009; Castilho
et al. 2010). The synthesis of the potentially immu-
nogenic fucose and xylose epitopes may also be
avoided by inhibiting the expression of the respon-
sible glycosyltransferases such as demonstrated in
tobacco, duckweed and moss (Huether et al. 2005;
Cox et al. 2006; Strasser et al. 2008).
Alternatively, processing of N-glycans on thera-
peutic proteins may be controlled by retention of the
protein in the ER (Van Droogenbroeck et al. 2007;
Ko et al. 2003). In this case processing will not
proceed beyond Man7GlcNAc2 type glycans, since
the enzymes involved in further N-glycan modification
are located in the downstream Golgi compartments.
However, also the presence of such high-mannose
type glycans on plant produced and ER-retained
therapeutic proteins may be undesirable for specific
molecules, for example because they may contribute
to a higher clearance rate of antibodies in mamma-
lian hosts (Wright and Morrison 1998; Bardor et al.
2003; Ko et al. 2003). Recently we identified ALG3
gene from Arabidopsis thaliana as the Dol-P-
Man:Man5GlcNAc2-PP-Dol a1,3-mannosyl transfer-
ase which is involved in the build-up of dolichol-
linked high-mannose type glycans in the ER
(Henquet et al. 2008). A homozygous T-DNA
insertion mutant, alg3-2, with only very low levels
of wild-type ALG3 activity was identified. In this
mutant, mostly truncated aberrant Man5GlcNAc2
instead of Man9GlcNAc2 glycans are transferred
from dolichol to the glycoproteins. Consequently,
most processing steps in the ER are skipped and ER
resident glycoproteins in alg3-2 plants are almost
uniformly modified by an abnormal Man5GlcNAc2
glycan (Henquet et al. 2008). Both the lack of high
mannose glycans and the uniformity of protein
glycan structures on ER-resident proteins in alg3-2
make this mutant an interesting host to test for
improved quality of recombinant protein production
in plants.
Previously, Arabidopsis plants have been described
producing in seeds high levels of recombinant MBP10,
a scFv-Fc directed against the Maltose Binding Pro-
tein, with a KDEL ER retention tag. N-glycans present
on these antibodies were predominantly of the
Man8GlcNAc2 and Man7GlcNAc2 isoforms, while in
addition significant amounts of the antibody chains
were not glycosylated (Van Droogenbroeck et al.
2007). The MBP10 transgene was introduced through
crossing into the alg3-2 mutant background and the
properties of MBP10, as produced in wild-type and
alg3-2 plants were compared.
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Results
N-glycan profile in wild-type and alg3-2 mutant
Arabidopsis seeds
The alg3-2 plant was shown to have only very low
expression of the ALG3 gene, which results in an
altered N-glycan profile on glycoproteins from leaves
(Henquet et al. 2008). To determine whether this
phenotype is also displayed in seeds of the alg3-2
mutant, the N-glycan profile of the total glycoprotein
pool of wild-type and mutant Arabidopsis seeds was
compared. Proteins were extracted from wild-type
and alg3-2 seeds and N-glycans were released by
PNGase A treatment. Each N-glycan pool was
analyzed by MALDI-TOF.
No Man9-6GlcNAc2 type glycans were detected in
seeds of the mutant plants and instead particularly
Man3GlcNAc2, Man4GlcNAc2 and some Man5Glc-
NAc2 N-glycans accumulated. This analysis does not
distinguish between the wild-type Man5GlcNAc2 and
the aberrant Man5GlcNAc2 from the mutant glyco-
sylation pathway (Supplemental Fig. 1), which con-
tains a-1,2 linked mannose residues (Henquet et al.
2008). The Man5GlcNAc2 glycans from the alg3-2
mutant with a-1,2 linked mannoses are sensitive to
a(1,2)-mannosidase (?ManI) treatment. Therefore,
the N-glycan pools were treated with a(1,2)-mannos-
idase (Supplemental Table 1: ?ManI). Results
showed that in the ManI treated N-glycan fraction
from wild-type all high mannose type N-glycans had
been trimmed, resulting in an increase of the ManI-
resistant Man5GlcNAc2 glycan pool (Supplemental
Table 1), demonstrating the effectiveness of the ManI
treatment. In the alg3-2 N-glycan fraction, the
mannose type glycans were all trimmed to Man3Glc-
NAc2, proving that the Man4GlcNAc2 and Man5Glc-
NAc2 contain a-1,2 mannose residues and therefore
are derived from the mutant pathway (Henquet et al.
2008).
The MALDI-TOF analysis suggests a lower level
of complex type N-glycans in alg3-2 seeds compare
to wild type (43.4 and 55.9%, respectively), while on
glycoproteins isolated from leaf tissue, the fraction of
complex type N-glycans is higher compared to wild
type (62.2 vs. 48.1% respectively: see Henquet et al.
2008) To further investigate the level of complex
glycosylation in alg3-2 seeds, proteins from wild-
type, alg3-2 and from homozygous cgl mutant, which
lack complex type glycans because of a defect in
N-acetylglucosaminyltransferase I (von Schaewen
et al. 1993), were isolated from seeds and probed in
an ELISA assay. The presence of glycoproteins with
complex type glycans containing xylose and/or
fucose can be detected with rabbit anti-horseradish
peroxidase (HRP) antibodies, which are mostly
directed against the complex type glycans. A differ-
ence of signal of proteins with N-linked complex type
glycans was observed in the homozygous alg3-2
mutant strain and wild-type plants (supplemental
Fig. 2), indicating that in contrast to leaves, in seeds
the mutation does affect the level of complex glycans
on glycoproteins (Henquet et al. 2008).
Characterization of N-glycans on MBP10
in wild-type and alg3-2 seeds
MBP10 consists of a single chain Fc fused to an Fv
directed against Maltose Binding Protein (MBP) and
an additional KDEL sequence to retain the protein
product in the ER. To determine the effect of the
alg3-2 mutation on recombinant antibodies retained
in the ER of seeds, we crossed wild-type Arabidopsis
transgenic plants, homozygous for the MBP10 anti-
body expression construct (Van Droogenbroeck et al.
2007), with homozygous alg3-2 mutant plants. F1
progeny plants were allowed to self pollinate and F2
plants, homozygous for both the MBP10 expression
construct and the alg3-2 mutation were selected as
described in materials and methods. To compare the
production of MBP10 in wild-type and alg3-2 seeds,
proteins were isolated from the seeds, separated by
SDS–PAGE under reducing conditions and visualized
by Commassie blue staining. Both in wild-type and
Table 1 Relative amounts of N-glycans on MBP10 in
wild-type and alg3-2 seeds
Glycan structures Wild type alg3-2
% of total % of total
Hex3GlcNAc2 n.d. n.d.
Hex4GlcNAc2 n.d. n.d.
Hex5GlcNAc2 n.d. 86.1
Hex6GlcNAc2 n.d. n.d.
Hex7GlcNAc2 26.6 13.9
Hex8GlcNAc2 73.4 n.d.
Hex9GlcNAc2 n.d. n.d.
n.d. not detectable
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alg3-2 plants, similar high levels of scFv-Fc mono-
mers migrated as major doublet bands at the expected
molecular mass of *55 kDa (Fig. 1, lanes 1 and 2),
indicating that the alg3-2 mutation does not signif-
icantly affect the antibody accumulation level.
The two bands at about 55 kDa reflect the
glycosylated and unglycosylated form of the scFv-
Fc monomers (Van Droogenbroeck et al. 2007).
Indeed, in both samples, the scFv-Fc doublet col-
lapsed to a single band after treatment with PNGase
F, with the same apparent molecular size as the lower
band of the original doublet (Fig. 2, lanes 3 and 6).
As complex type N-glycans with Golgi specific
modifications containing a1,3-linked fucose residues
are resistant to PNGase F, the sensitivity of the upper
band to PNGase F also indicates that the MPB10 is
not decorated with complex type N-glycans, in line
with it being retained to the ER. Additional confir-
mation that the MBP10 in wild-type contains high
mannose type N-glycans came from its sensitivity to
EndoH treatment (Fig. 2, compare lane 1 and 2). In
contrast, N-glycans on MBP10 from alg3-2 were
resistant to Endo H, indicating that in alg3-2 seeds,
the glycans on the antibodies are not of the same high
mannose type. Because the N-glycans on MPB10 in
alg3-2 seeds are sensitive to PNGase F but resistant
to Endo H they are most likely derived from the
mutant pathway in alg3-2 (Fig. 2, compare lane 5 and
6) in which an aberrant Man5GlcNAc2 glycan is
transferred from lipid to protein.
In complementary experiments, the N-glycans on
MBP produced in wild-type or alg3-2 seeds were
analyzed by MALDI-TOF. The MBP10 protein from
both wild-type and alg3-2 was isolated from a
reducing denaturing SDS–PAGE gel, treated with
trypsin and the peptide mixture was subjected to
analysis by MALDI-TOF. In contrast to earlier
LCMS analysis of N-glycans on MBP10 in wild-
type (Van Droogenbroeck et al. 2007), no partial
tryptic glycopeptides masses were detected in our
analysis. Similar as to previously observed (Van
Droogenbroeck et al. 2007), the most abundant
glycans on scFv-Fc isolated from wild-type seeds
were Man8GlcNAc2 and Man7GlcNAc2 (Table 1).
The scFv-Fc glycopeptides from alg3-2 seeds were
mostly modified by Man5GlcNAc2. However, also a
significant pool was decorated with Hex7GlcNAc2
type glycans which could be wild type Man7GlcNAc2
or Glc2Man5GlcNAc2 glycans. This needs further
investigation.
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Fig. 1 Production of MBP10 in wild-type and alg3-2 seeds.
Total seed protein fractions from wild-type expressing MBP10
(lane 1), alg3-2 expressing MBP10 (lane 2) and untransformed
wild-type (lane 3) were separated by SDS–PAGE and
visualized by Commassie staining
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Fig. 2 N-glycan analysis of MBP10 in wild-type and alg3-2
seeds. Isolated total seed protein fractions from wild-type
expressing MBP10 (lane 1), alg3-2 expressing MBP10 (lane 4),
before and after overnight incubation with EndoH (lanes 2
and 5) or PNGase F (lanes 3 and 6), were separated by
SDS–PAGE, and visualized by Commassie staining
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Underglycosylation of MBP from wild type
and alg3-2 seeds
To determine the amount of nonglycosylated MBP10
derived from wild type and alg3-2 seeds, the MBP10
protein was isolated with a Protein A column,
deglycosylated with PNGase and treated with trypsin.
The MBP10 peptide mixtures from wild type and
alg3-2 were subjected LC–MS analysis. Since aspar-
agine (N) is converted to aspartic acid (D) in this
PNGase F reaction, glycosylation sites can be iden-
tified by a mass increase of 1 Dalton. This mass
difference can be measured by Q-TOF LC–MS and
the ratio of N and D gives an indication for the ratio
between non-glycosylated and deglycosylation of
MBP10. From Fig. 2 it was already visible that both
MBP10 variants contain nonglycosylated as well as
glycosylated antibodies. The results show a signifi-
cant increase in the amount of nonglycosylated
MBP10 isolated from alg3-2 seeds (31.0% ± 2.3%)
as compared to wild type seeds (22.4% ± 0.7%)
(Fig. 3, Supplemental Fig. 3).
MBP10 expression in seeds affects glycosylation
of endogenous glycoproteins
The fraction of underglycosylated MBP10 in both
wild type and alg3-2 may suggest that the glycosyl-
ation capacity of the cells in developing seeds may
not be able to cope with the elevated level of
glycoprotein expression. To determine whether this
effect of high heterologous MBP10 production levels
on glycosylation also affects endogenous ER resident
proteins, the glycosylation of protein disulfide isom-
erase (PDI) was investigated in wild-type and alg3-2
seeds from plants with or without seed specific
MBP10 expression. Indeed, PDI showed no signs of
underglycosylation in wild type, while underglycosy-
lation was weak in wild-type ? MBP10, stronger in
alg3-2 and strongest in alg3-2 ? MBP10 (Fig. 4).
Apparently, the ectopic MBP10 expression in both
wild type and alg3-2 causes competition for glyco-
sylation activity, resulting in PDI underglycosylation
in the ER. Glycan analysis showed that the glycans of
PDI from wild type were cleaved by EndoH (data not
shown), while the glycans on MBP10 from alg3-2
seeds were resistant to EndoH treatment, indicating
that these are not normal high-mannose type glycans
and therefore most likely derived from the mutant
pathway (aberrant Man5-3GlcNAc2 type). A similar
difference was observed for glycans on PDI in WT
and alg3-2 leaf protein extracts (Henquet et al. 2008).
Glycan occupancy of MBP10 dimers from wild
type and alg3-2
Since the results show that MBP10 scFv-Fc mono-
mers from both wild type and alg3-2 mutant seeds
exist in glycosylated and unglycosylated states, it was
of interest to determine the fraction MBP10 dimers
consisting of homo-glycosylated, hetero-glycosylated
and homo-unglycosylated MPB10 scFv-Fc dimers in
wild type and alg3-2 seeds. We therefore performed
native mass spectrometric analysis on intact scFv-Fc
dimers (Heck 2008). The mass difference between
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Fig. 3 Level of underglycosylated MBP10 isolated from wild-
type and alg3-2 seeds determined by Q-TOF LCMS. MBP10
isolated from total seed protein fractions from wild-type and
alg3-2 expressing MBP10 after overnight incubation with
PNGase F were analyzed by Q-TOF LC–MS. The ratio of N-D
resulting from the PNGase reaction gives the ratio between
non- and deglycosylation of MBP10
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the different glycoforms in each of the samples
corresponded with the mass of the major N-glycan
present on wild type or alg3-2 MBP10 (Hex8Glc-
NAc2 and Hex5GlcNAc2, respectively). The results
show that MBP10 dimers from both wild type and
alg3-2 contain either no, one or two glycans (Table 2;
H0, H1, H2). This ratio is close to the theoretical ratio
between H0:H1:H2 based on dimerisation of ungly-
cosylated and glycosylated chains in a random
manner, which suggests no preference in dimer
formation (Supplemental Table 2).
Binding of MBP10 from wild-type and alg3-2
to the antigen
The Fv of MBP10 contains a binding site to the
maltose binding protein (Van Droogenbroeck et al.
2007). We tested whether the affinity of MBP10 to
maltose binding protein was affected by the differ-
ence in glycan structure on MBP10 in wild type and
MBP10 in the alg3-2 mutant plants. Purified MBP10
antibodies from both wild type and alg3-2 were tested
for reactivity with maltose binding protein by ELISA
for binding against MBP antigen. The results show
that MBP10 from alg3-2 has a slightly lower binding
affinity for the antigen than MBP10 from wild type
seeds at high concentrations but that they are
indistinguishable at lower concentrations (Supple-
mental Fig. 4).
Discussion
MBP10 expression affects N-glycosylation
levels in seeds
Here we have compared the production of the MBP10
antibody in wild type and alg3-2 mutant background.
The alg3-2 background has as potential advantage
that glycan modifications on ER resident proteins are
highly uniform. On MBP10 protein, next to the high
level of aberrant Man5GlcNac2 glycan, a low level of
normal high mannose type N-glycans was detected,
which apparently resulted from leakage of the alg3-2
mutation. (Henquet et al. 2008).
The total amount of complex type N-glycans, as
detected by MALDI-TOF, was lower in alg3-2 seeds
compared to wild-type (Supplemental Table 1:
43.4% in alg3-2 compared to 55.9% in wild-type).
In contrast, in leaves the relative level of complex
glycosylation was similar for wild-type and the alg3-
2 mutant (Henquet et al. 2008). The difference in
level of complex N-glycans between wild type and
alg3-2 seed proteins was confirmed by an ELISA
assay (Supplemental Fig. 2). The difference could
be related to a reduced substrate specificity of
N-acetylglucosaminyltransferase I (GnTI) for the
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Fig. 4 PDI in wild-type and alg3-2 seeds with or without
MBP10 expression Western blot analysis of PDI in wild-type
and alg3-2 seeds with or without MBP10 expression. Proteins
were isolated from wild-type and alg3-2 seeds and subjected to
immunoblotting with anti-PDI. * indicates under glycosylated
PDI protein
Table 2 Glycan occupancy on MBP10 dimers (zero glycans:
H0, one glycan: H1, two glycans H2) in wild-type and alg3-2
seeds
Sample Molecular
mass (Da)
Mass
difference
Expected mass
difference (Da)
Wild type H0 107713.2 – –
Wild type H1 109383.5 ?1670.3 1702.0
Wild type H2 111080.2 ?1696.7 1702.0
alg3-2 H0 107666.9 –
alg3-2 H1 108882.6 ?1215.7 1216.0
alg3-2 H2 110092.0 ?1209.4 1216.0
Glycan occupancy was based on the major mass difference
between the unglycosylated form (H0) and other identified
total MPB10 dimer masses. The theoretical molecular weight
of unglycosylated MPB10 scFv-Fc dimer (H0): 107584.4 Da.
Expected mass difference is based on the most common
occurring glycan on MBP10 in wild-type (Hex8GlcNAc2) or
alg3-2 (Hex5GlcNAc) (see Table 1
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aberrant Man3GlcNAc2 N-glycans which are pro-
duced in alg3-2 after trimming of aberrant N-glycan
structures by ManI. Indeed, in vitro experiments have
shown that, for both plant and mammalian GnTI, both
substrates can be used but that Man5GlcNAc2 is the
preferred substrate (Schachter et al. 2003; Strasser
et al. 2005). It could be that with the elevated
secretion activity in seeds compared to leaves, the
GnTI levels in seeds are more limiting than in leaves.
Alternatively, or in addition, it could be that the
elevated secretion activity in seeds favors sequester-
ing of proteins with aberrant glycans to ER derived
protein storage bodies, resulting in diminished trans-
port of endogenous proteins to and through the Golgi.
The levels of accumulate MBP10 protein were
similar in alg3-2 and wild type seeds (Fig. 1).
However, the production of MBP10 in seeds did
affect the glycosylation status of endogenous glyco-
proteins like PDI (Fig. 4). This effect seems to be
stronger in alg3-2 seeds with MBP10 expression than
in wild type seeds with MBP10 expression. The
results suggest a limit to the N-glycosylation capacity
in relation to the elevated protein secretion activity in
the ER of developing seeds. In the alg3-2 back-
ground, the under glycosylated levels of MBP10 and
PDI were even higher, which may be caused by
reduced affinity of the oligosaccharyltransferase
(OST) complex for lipid bound aberrant type glycans.
Aberrant glycans have no effect on physical
properties of MBP10
The overall binding properties of MBP10 as produced
in the alg3-2 background were not much different
from those of MBP10 as produced in wild type seeds
(Supplemental Fig. 4). Although the binding of
MBP10 to the maltose binding protein is not depen-
dent on dimerisation of the antibody, it was of interest
to determine whether dimer formation showed pref-
erences for homodimer (fully glycosylated or fully
unglycosylated) or heterodimer (one glycosylated and
one not glycosylated) formation. Results showed both
homodimer and heterodimer antibodies are present.
The relative abundance, based on peak intensities of
each of the glycoforms, was similar to the predicted
abundance based on random associations (Table 2
and Supplemental Table 2), indicating that the
difference in glycan structure is of no influence in
dimerisation.
Materials and methods
Plant materials and growth conditions
Seeds of Arabidopsis thaliana lines were sown on
9 cm 0.8% daishin agar Petri dishes and placed in a
cold room at 4C for 2 days in the dark to promote
uniform germination. Germination and plant culture
were performed in a climate chamber (20/15C day/
night temperatures; 250 lmol light m-2s-1 at plant
level during 12 h/day and 75% relative humidity).
Construction of alg3-2/MBP plants
The alg3-2/MBP plants were obtained by crossing
alg3-2 mutant plants with wild-type Col0 plants
containing the MBP antibody gene. F2 generation
was screened for homozygous alg3-2 T-DNA inser-
tion with PCR on genomic DNA using the forward
primer Alg3-F2.2 (50-CGTTCAGTGATGTATCAG
CCTCACGG-30) and the reverse primer Alg3-R2
(50-GGATTTAGGGTGTTCTTTGAGCTGATAAG
G-30). Proteins from seeds from homozygous alg3-2
F2 plants were separated on SDS–PAGE gel and
stained with Commassie Brilliant blue to select for
plants containing the anti-MBP antibody.
SDS–PAGE and immunoblotting
Plant material was ground in liquid nitrogen, resus-
pended in 10 ll phosphate-buffered saline (137 mM
NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2
PO4, pH 7.4) per mg of plant material and centrifuged.
An aliquot of the supernatant was immediately mixed
with SDS–polyacrylamide gel electrophoresis
(PAGE) loading buffer, denatured at 95C for 5 min
and subjected to SDS–PAGE (8 or 12.5%) under
reducing conditions. Protein gel blotting was per-
formed using polyvinylidene difluoride membranes,
blocked with 5% (w/v) nonfat dry milk in Tris-
buffered saline (20 mM Tris–HCl, pH 7.6, and
137 mM NaCl) with 0.05% Tween 20. The mem-
branes were probed with anti-PDI (1:5000; Rosebio-
tech). Detection of bound primary antibodies was
performed with BCIP/NBT after incubation with goat
anti-rabbit antibodies. PNGase F and Endo H were
purchased from New England Biolabs for glycosyla-
tion analysis of PDI and MBP10 and used according to
the suggested methods along with the manufacturer’s
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recommended buffers. The reactions were terminated
by boiling in SDS-loading buffer.
Purification of the MBP10 antibody
MBP10 antibodies were purified from crude seed
extracts with a Vivapure Miniprep A kit (Sartorius)
according to the manufacturer’s protocol.
ELISA
Microtiter plates were coated with protein extract
from seeds overnight at 4C in 0.1 M sodium
carbonate buffer, pH 9.6. The plates were washed
with phosphate-buffered saline (PBS) containing
0.05% Tween 20 and blocked with PBS-T containing
5% skimmed milk for 1 h at RT. After the washing
the plates were incubated for 1 h at RT with
polyclonal anti-HRP antibody (Sigma) diluted
1:2,000. Detection of bound primary antibodies was
performed with AP substrate after incubation with
goat anti-rabbit antibodies.
Isolation of N-glycans and a(1,2)-mannosidase
treatment
Seeds of Arabidopsis plants were used for N-glycans
analysis. Proteins for N-glycan purification were
extracted from 100 mg of seeds and digested with
pepsin. Bound N-glycans were released by PNGase A
(Roche) as described previously (Bakker et al. 2006).
Aspergillus satoi a(1,2)-mannosidase (10 mU/ml;
Pro-enzyme, Glyko) digestions were performed in
the supplied buffer for 24 h at 37C. Reactions were
then diluted with 0.5 ml of milliQ water and desalted
by passage through a 500 mg C18 column (Varian).
N-glycan analysis
Purified N-glycans were dissolved in 5 mM NaAc
and mixed with an equal volume of 1% 2,5-
dihydroxybenzoic acid in 50% acetonitrile. One-
microliter aliquots were spotted onto a stainless-steel
sample plate and dried under a stream of air at room
temperature. Positive-ion MALDI-TOF spectra of
[M ? Na] ? adducts were recorded on an Ultraflex
mass spectrometer (Bruker, Billerica, MA) fitted with
delayed extraction and a nitrogen laser (337 nm). A
maltodextrin series was used as an external molecular
weight standard. Spectra were generated from the
sum of at least 1,000 laser pulses.
MALDI glycopeptide analysis
The protein A purified MBP10 protein from both wild
type and alg3-2 was isolated from a reducing
denaturing SDS–PAGE gel, treated with trypsin and
the peptide mixture was desalted using C18 zip-tip
(Millipore). The purified (glyco)peptide mixture was
dissolved in milliQ water and spotted onto a stainless-
steel MALDI target plate. Samples spotted onto
MALDI plate were overlaid with an equal volume of
dihydroxybenzoic acid (DHB, 2 mg/ml 30% ACN
with 0.1% TFA) and allowed to dry in air at room
temperature. Positive-ion MALDI-TOF spectra were
recorded on an Ultraflex mass spectrometer (Bruker,
Billerica, MA) fitted with delayed extraction and a
nitrogen laser (337 nm). A maltodextrin series was
used as an external molecular weight standard.
Spectra were generated from the sum of at least
1,000 laser pulses. The glycans on the glycopeptides
were subsequently deduced by subtracting the mass
of the predicted tryptic scFv-Fc peptide (EEQYNS-
TYR; 1188.5 Da) from the observed masses of the
glycopeptides.
Native mass spectrometry
The buffers of the proteins were exchanged to
100 mM ammonium acetate pH 7.5, using ultrafil-
tration units with a cutoff of 10,000 Da (Millipore,
Bedford, USA). All antibodies were analyzed at a
concentration of 5 lM. Electrospray ionization cap-
illaries were prepared in house as described previ-
ously (van den Heuvel et al. 2006). Analysis was
performed on an LCT in positive ion mode (Waters,
UK). Typically mass spectra were recorded with a
capillary voltage of 1.2 kV and a cone voltage of
200 V. The pressure in the source region was raised
to approximately 7 mbar, the pressure in the ToF was
2.7 9 10-6 mbar. All spectra were calibrated using a
solution of 25 mg/ml cesium iodide in MilliQ water.
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